Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Truth InitiativeFDA Must Maintain Strong Scientific Review Process for New Tobacco Products and Crack Down on Illegal Marketplace to Protect Public HealthStatement from Kathy Crosby, CEO and President of Truth Initiative — Today, the U.S. Food and Drug Administration announced that it plans to evaluate changes to the framework for applications for new tobacco products like e-cigarettes and nicotine...
- MDCloneUniversity Medical Center Göttingen Takes a New Approach to the Use of Clinical DataUMG is advancing its data integration center and becomes the first German university hospital to introduce MDClone's internationally established ADAMS model. Göttingen, Germany and — The University Medical Center Göttingen (UMG) is the...
- Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 DeficiencySTOCKHOLM, SWEDEN, Sept. 28 2026. – Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITATE® (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome). EMCITATE is not recommended for the treatment of primary hypothyroidism. EMCITATE is the first FDA-approved treatment option for patients with MCT8 deficiency in the United States.
- Slate Asset ManagementSlate Delivers Strong Return for Investors in North American Essential Real Estate StrategyTORONTO, September 28, 2026--Slate Asset Management ("Slate" or the "Firm"), a global investor and manager focused on essential real estate and infrastructure, today announced that in connection with the proposed acquisition of Slate Grocery REIT, Slate’s North American essential real estate strategy has agreed to sell its joint venture interests in the grocery-anchored portfolio to Brixmor and Everview. The proposed sale delivers a strong return for investors in the strategy and reflects the de
- Meitheal Pharmaceuticals, Inc.Meitheal Pharmaceuticals Announces FDA Approval of High-Concentration Formulation of YUSIMRY®, a Biosimilar to Humira®CHICAGO, September 28, 2026--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced that the U.S. Food and Drug Administration ("FDA") has approved a high-concentration formulation ("HCF") for YUSIMRY® (adalimumab-aqvh), as an interchangeable biosimilar to Humira®.
- Google3 ways this grocer cooks for 200 guests with GeminiCompanies: Alphabet Inc.Edy Massih uses Gemini to transform regular recipes into massive catering spreads, automate grocery orders, and adapt menus for dietary restrictions.
- DDC Enterprises Inc.DDC Enterprise Filed Annual Report on Form 20-F on April 21, 2026DDC Enterprise Limited (NYSEAMERICAN: DDC) (“DDC” or the “Company”), a leading multi-brand Asian consumer food company with a growing strategic bitcoin treasury, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the Securities and Exchange Commission on April 21, 2026. The annual report on Form 20-F can be accessed on the Company’s investor relations website at https://ir.ddc.xyz/financials/financial-results or on the SEC’s website at www.sec.gov.
- NovonesisNovonesis celebrates major expansion of West Allis production facility, strengthening North American dairy innovation and manufacturingInvestment increases production capacity, supports booming consumer demand and reinforces Wisconsin's leadership in dairy biosolutions
- Phillips Edison & Company Inc. Invites You to Join Its Third Quarter 2026 Earnings Conference CallPhillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, will announce its Third Quarter 2026 earnings results on Monday, October 26, 2026, after the market closes. PECO’s earnings release and financial supplement will be posted on the Investor Relations section of the Company’s website at https://investors.phillipsedison.com/. Chairman and Chief Executive Officer Jeff Edison, President Bob Myers and Chief Financial Officer John Caulfield will host an earnings conference call, which will also be webcast, on Tuesday, October 27, 2026, at 12:00 p.m. ET.
- SamsungSamsung TV Plus Expands Global Creator Lineup to More MarketsCompanies: Samsung ElectronicsSamsung TV Plus is expanding its creator offerings to more markets worldwide. Samsung Electronics’ subscription-free streaming service introduced new creator-led channels across Australia, New Zealand, the Philippines, Singapore, Thailand, and the United Kingdom — while extending existing creator channels to Brazil and Mexico. Spanning lifestyle, food, sports, news, and science, the additions broaden access to […]
- Yili GroupYili Shares China's Whole-Value-Chain Dairy Symbiosis Model at FAO Global ConferenceYili Group presented a China-based model for whole-value-chain symbiosis at the Food and Agriculture Organization of the United Nations' (FAO) inaugural Global Conference for Actions on One Health in Agrifood Systems. One Health seeks to sustainably...
- THE ROSEN LAW FIRM, P. A.SMPL Deadline: SMPL Investors Have Opportunity to Lead The Simply Good Foods Company Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of The Simply Good Foods Company (NASDAQ: SMPL) between October 24, 2024 and April 8, 2026, inclusive (the "Class Period"), of the important October 13, 2026...